We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Provides Prognosis of Tumor Drug Response

By LabMedica International staff writers
Posted on 25 Jun 2012
The number of cancer cells in blood samples taken before and after treatment for advanced neuroendocrine tumors could provide a “snapshot” of how well patients are responding to treatment. More...


By monitoring cancer cells circulating in the blood, doctors may be able to predict treatment success within weeks of starting treatment for this rare cancer type, which most commonly affects the gut or pancreas.

Scientists at the University College London Cancer Institute (UK) analyzed blood samples from 118 patients with advanced neuroendocrine cancers attending the Neuroendocrine Tumor Unit at the Royal Free Hospital (London, UK). They compared the numbers of individual tumor cells present in samples taken before and after treatment.

Patients with circulating tumor cells (CTCs) in the blood at the start of treatment were around eight times more likely to die from their disease, compared to those without CTCs. Following treatment, patients whose CTC levels fell by more than two thirds within five weeks tended to have the best outcomes, while those whose CTC levels rose by more than a third did the worst.

Doctors normally rely on computed tomography (CT) or magnetic resonance imaging (MRI) scans to tell them if a treatment is working, but cutting-edge CTC testing can provide an overall snapshot of the tumor's development, without the need to wait for changes in its size to become visible on scans. Tim Meyer MD, the study leader, said, "By using state-of-the-art technology to count individual tumor cells circulating in the blood stream, we’ve been able to show how a simple blood test could help monitor treatment response and predict how fast the disease will progress."

Joanna Reynolds, PhD, the director of UK’s Cancer Research centers, said, "Advanced cancers often consist of lots of smaller tumors around the body, many of which will be too tiny to be picked up by traditional imaging techniques, making it difficult to judge how well a drug is working. This study highlights a potential way to monitor response in real time across all cancer sites, so doctors know sooner if a treatment isn’t working. Although at an early stage, this is an exciting area of exploration and we look forward to seeing how it progresses." The study was presented on June 4, 2012, at the American Society for Clinical Oncology cancer conference held in Chicago (IL, USA).

Related Links:

University College London Cancer Institute
Royal Free Hospital



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.